Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery DiseaseMarc P. Bonaca, Marc S. Sabatine, Armando Lira Pineda et al.|Circulation|2017Cited by 754
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trialMarc S. Sabatine, Terje R. Pedersen, Lawrence A. Leiter et al.|The Lancet Diabetes & Endocrinology|2017Cited by 595